PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/127	A1	(11) International Publication Number: WO 96/10393
		(43) International Publication Date: 11 April 1996 (11.04.96)

(21) International Application Number: PCT/IB95/00802

(22) International Filing Date: 28 September 1995 (28.09.95)

(30) Priority Data:
94810570.5 30 September 1994 (30.09.94) EP
(34) Countries for which the regional or international application was filed: AT et al.

(71) Applicant: BRACCO RESEARCH S.A. [CH/CH]; 7, route de Drize, CH-1227 Carouge (CH).

(72) Inventors: TOURNIER, Hervé; 300, Le Riondet, F-74520 Valleiry (FR). SCHNEIDER, Michel; 34, route d'Annecy, CH-1256 Troinex (CH). GUILLOT, Christian; Les Eplanes, F-74160 Le Châble-Beaumont (FR).

(74) Agent: TOMOV-GRISOGONO, Nenad; Bracco Research S.A., 7, route de Drize, CH-1227 Carouge (CH).


(81) Designated States: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: LIPOSOMES WITH ENHANCED ENTRAPMENT CAPACITY, METHOD AND USE

(57) Abstract

The invention relates to a dry deposit as a precursor to liposome vesicles, the precursor being a three-dimensional expanded structure with bulk density between .01 and .001 g/cm^3. The invention also concerns a method of making liposome vesicles with an enhanced entrapment capacity by dissolving one or more film forming lipids in at least one organic solvent to form a solution in a reaction vessel, evaporating the solvent to form an expanded three dimensional porous lipid structure, contacting the lipid deposit with an aqueous carrier phase, and producing liposome vesicles entrapping the carrier phase as well as an apparatus comprising an array of tubing or an inert packing which serves as a material support or a matrix surface for the deposition of lipids produced according to the method.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	**GB**	United Kingdom	**MR**	Mauritania
AU	Australia	**GE**	Georgia	**MW**	Malawi
BB	Barbados	**GN**	Guinea	**NE**	Niger
BE	Belgium	**GR**	Greece	**NL**	Netherlands
BF	Burkina Faso	**HU**	Hungary	**NO**	Norway
BG	Bulgaria	**IE**	Ireland	**NZ**	New Zealand
BJ	Benin	**IT**	Italy	**PL**	Poland
BR	Brazil	**JP**	Japan	**PT**	Portugal
BY	Belarus	**KE**	Kenya	**RO**	Romania
CA	Canada	**KG**	Kyrgystan	**RU**	Russian Federation
CF	Central African Republic	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CG	Congo			**SE**	Sweden
CH	Switzerland	**KR**	Republic of Korea	**SI**	Slovenia
CI	Côte d'Ivoire	**KZ**	Kazakhstan	**SK**	Slovakia
CM	Cameroon	**LI**	Liechtenstein	**SN**	Senegal
CN	China	**LK**	Sri Lanka	**TD**	Chad
CS	Czechoslovakia	**LU**	Luxembourg	**TG**	Togo
CZ	Czech Republic	**LV**	Latvia	**TJ**	Tajikistan
DE	Germany	**MC**	Monaco	**TT**	Trinidad and Tobago
DK	Denmark	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**US**	United States of America
FI	Finland	**ML**	Mali	**UZ**	Uzbekistan
FR	France	**MN**	Mongolia	**VN**	Viet Nam
GA	Gabon				

LIPOSOMES WITH ENHANCED ENTRAPMENT CAPACITY, METHOD AND USE

Technical Field

The invention relates to a liposome vesicle precursor in the form of a dry lipid deposit and a method of making liposome vesicles with enhanced entrapment capacity by dissolving one or more film forming lipids in at least one organic solvent in a reaction vessel, depositing the lipids by evaporation of the solvent, contacting the lipid deposit with an aqueous solution carrier phase, and producing liposome vesicles entrapping the solution. The invention also concerns a an apparatus for carrying out the method, contrast agents comprising the liposome vesicle precursor and a method of making contrast agents using the precursor.

Background Art

Liposomes vesicles whose binding envelope consists of bi- or multilayer of lipid molecules have been long recognised as drug delivery systems which can improve therapeutic and diagnostic effectiveness of many drugs and contrast agents. Experiments with a number of different antibiotics and X-ray contrast agents have shown that better therapeutic activity or better contrast with a higher level of safety may be achieved by encapsulating drugs and contrast agents with liposomes. Great interest in liposomes as encapsulating systems for drugs has revealed that a successful development and commercialisation of such products requires reproducible methods of large scale production of lipid vesicles with suitable characteristics. Consequently, a search for methods which will consistently produce liposome vesicles of the required size and concentration, size distribution and entrapping capacity regardless of the nature of lipid mixture have been initiated. Such methods ought to provide liposomes with consistent active substance to lipid ratio while respecting currently accepted good manufacturing practices. As a result of the search, and due to the fact that the liposome behaviour can vary substantially with various production parameters, many different methods of manufacture have been proposed so far.

Conventional liposome preparation methods include a number of steps in which multi- or the bilayer-forming components (phospholipids or mixtures of phospholipids with other lipids e.g. cholesterol) are dissolved in a volatile organic solvent or solvent mixture in a round bottom flask followed by evaporation of the solvent under conditions (temperature and pressure) which will prevent phase separation. Upon solvent removal, a dry lipid mixture, usually in form of a film deposit on the walls of the reactor, is hydrated with an aqueous medium which may contain dissolved buffers, salts, conditioning agents and an active substance to be entrapped. Liposomes will form in the hydration step whereby a proportion of the aqueous medium becomes encapsulated in the liposomes. The hydration can be performed with or without energising the solution by means of stirring, sonication or microfluidisation with subsequent extrusion through one or more polycarbonate filters. The free non-encapsulated active substance can be separated for recovery and the product is filtered, sterilised, optionally lyophilised, and packed.

Hydration, more than any other step, influences the type of liposomes formed (size, number of lipid layers, entrapped volume). The nature of the dried lipid, its surface area, and its porosity are of particular importance. Thus it has been established that the hydration and entrapping process are most efficient when the film of dry lipids is kept thin. This means that greater the lipid quantity, greater the surface for deposition of the lipids is required, it also means that even though glass beads and other inert insoluble particles are used to increase the surface area available for film deposition, the thin film method remains largely a laboratory method.

Other methods of making liposomes involving injection of an organic solutions of lipids into an aqueous medium with continuous removal of solvent, use of spray drying, lyophilization, microemulsification and microfluidization, etc. have been proposed a number of publications or patents such as for example US-A-4,529,561, US-A-4,572,425, etc.

An attempt to solve problems of the scale-up of liposome production has been described in the US-A-4,935,171 (Vestar). There is

disclosed a method for preparing liposomes in commercial quantities by forming a homogeneous and uniform lipid film in a thin-film evaporator through evaporation of the organic solvent. After drying of the thin lipid film which is formed on the inner wall of the evaporator, the deposit is in situ hydrated with an aqueous phase under agitation provided by the rotor. Although the solution proposed in this document seems to be a step in the right direction the lipid film surface to the reactor volume ratio is only slightly, if not marginally, better than that of the round-bottom flasks used on laboratory scale. The reactor's space time yield or productivity is still far too low for the process to be economically sound and competitive.

Different aspects of the liposome manufacturing have been addressed and a number of improvements and different solutions to the problem of scale-up have been proposed. Documents such as for example WO-A-86/00238, WO-A-87/00043, US-A-4,737,323, US-A-4,753,788, and US-A-4,781,871 have suggested use of rapid freezing of previously prepared multi lamellar vesicles with subsequent freeze and thaw treatment to improve their entrapment capacity, use of extrusion technique of multilamellar liposomes to improve their size distribution, etc.

So far there has been no suggestion towards a large scale industrial method whose control of production parameters will allow reproducible process in which large volumes of liquid will be processed within a relatively small reactor space. All known processes of pilot or industrial scale would, typically, be linked to small batches in which processing of large volumes of dilute liposome solutions would require a lot of floor and reactor space as well as handling of large volumes of solutions and solvents. In reality due to relatively low space time yields or productivity of reactors these methods are too cumbersome and far too costly for a large scale commercial production.

Summary of the Invention

Briefly summarised the invention relates to a supported or unsupported liposome vesicle precursor in the from of a three dimensional structure of expanded lipids with bulk density below .1 g/cm^3 preferably below .08, more preferably between .05 and .001 and even

more preferably between .02 and .01. By supported structure it is meant that the lipid porous deposit is formed on an array or network of inert supporting material. The lipids forming the deposit are selected from synthetic or natural, saturated and unsaturated phospholipids including phosphatidic acid, phosphatidyl choline, phosphatidylethanol amine, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol and mixtures thereof. The lipids may further contain substances selected from dicetylphosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, α-tocopherol, stearic acid, stearyl amine and mixtures thereof.

The invention also concerns a method of making liposome vesicles with enhanced entrapment capacity by dissolving one or more film forming lipids in at least one organic solvent to form a solution. The solution of lipids is introduced into a suitable reaction vessel and subjected to evaporation whereby the drying lipids form expanded three dimensional porous structure whose bulk density is below .1 g/cm^3, preferably below .08, more preferably between .05 and .001 and even more preferably between .02 and .01. Thereafter, the porous structure is contacted with an aqueous carrier phase to produce liposome vesicles entrapping a portion of the carrier phase.

The invention further comprises an apparatus for the manufacture of liposomes with high entrapment capacity according to the above method comprising a reaction vessel with an inlet and an outlet, a connection to a vacuum, means for cooling or heating, a control means, and a packing comprising an array of a closely packed tubing of an inert material. Preferably, the tubing is stainless steel tubing with the inner diameter of between .5 mm and 5 mm and the wall thickness of between .5 mm and 2 mm. Alternatively, the packing, which may be stationary or moving e.g. fluidized, may comprise Raschig rings, hollow glass spheres, reticulated carbon, reticulated vitreous carbon, reticulated metal, glass or metal wool and glass or metal fibre.

The three dimensional lipid structures of the invention are very suitable for a large scale manufacture of liposomes with high entrapment capacity.

When incubated with an aqueous carrier phase containing a

contrast medium, the three dimensional lipid structures of the invention are particularly suitable for the manufacture of diagnostic contrast agents.

Brief Description of the Drawings

Figure 1 is a schematic diagram of the reactor with a cut-out showing the expanded three dimensional lipid structure of the invention.

Figure 2 is a schematic diagram of the reactor with an array of an inert tubing.

Figure 3 is a plot of lipid deposition vs concentration.

Figure 4 is a plot of lipid deposition vs linear velocity.

Figure 5 is a flow chart of the production of a contrast medium using the expanded lipid structures of the invention.

Detailed Description of the Invention

This invention is based on the unexpected finding that optimal liposome formation and enhanced reactor capacity are obtained if during the production of the vesicles, the lipid deposit obtained by evaporation of the solvent from an organic solution of one or more film forming lipids in at least one organic solvent, prior to contacting with an aqueous carrier phase, is expanded into a three dimensional structure whose bulk density is below .1 g/cm^3, preferably below .08, more preferably between .05 and .001 and even more preferably between .02 and .01. Although the exact reasons for such unexpected results have not been thoroughly established, it is assumed that the method provides an exceptionally large surface to volume ratio of the deposit whose subsequent hydration is therefore more efficient. High yields of liposomes of the desired size and distribution are thus produced by the method which is particularly easy to scale up and control. Having a large surface to volume ratio the expanded lipid structures improve the space time yield of reactors, whereby the technique becomes industrially very attractive. In addition, to ease scale-up and

promote high productivity, the method provides further advantages which include faster reactor turn around time, ease of control of the hydration step, reduced processing times, use of inexpensive materials, and finally use of the same reactor for deposition, solvent evaporation, hydration of the expanded lipid structure and sterilization of the liposome vesicles formed.

It has been established that the porous structures of pure lipids of the invention have very large surface to volume ratio. Unfortunately, due to the great fragility of the expanded structure the exact surface area of the unit of volume or weight of the expanded lipid structure could not have been established with great accuracy. However, a conservative estimate of the total surface area of 1 g of the expanded structure of the invention suggests that the total surface area may vary between .1 and 50 m^2 which implies surface to volume ratios of between 10 to .5 x 10^5.

The expanded three dimensional lipid structure may be obtained through evaporation of the organic solvent from a reaction vessel which contains an inert porous network or a support which serves as a material support or a matrix surface for the deposition of lipids. The inert network may be any convenient material with a relatively large surface to volume ratio and it may include an array of tubing or an array of inert packing such as hollow glass spheres, reticulated carbon, reticulated vitreous carbon, reticulated metal, glass, ceramic or metal wool and glass, ceramic or metal fibre. When an array of tubing is used the tubing dimensions should be chosen such that maximal ratio of surface to volume is achieved. The experiments carried out in the course of the development and characterisation of the reactor according to the invention have shown that in a given configuration the tubing with an inner diameter of between .5 mm and 5 mm and wall thickness between .5 and 2 mm has provided favourable results, however, another configuration of the reactor may favour other tubing dimensions. It has been established that since the lipid solution is spread over the inner and outer surface of the tubing by gravity an array of vertically arranged tubing is preferred although a helical arrangement is also possible.

In order to facilitate uniform deposition of the lipid films the inert packing may be gently fluidized or the reactor packed with Raschig rings

or any other inert material such as that mentioned above may be fed with the lipid solution from the top and left to gently trickle down the packing. It is believed that excellent results obtained in the trickle tower arrangement come from the fact that an efficient control of deposit thickness is achieved by the trickle fashion of contacting of the lipid solution and the support. The excess liquid being constantly removed whereby uniform liquid thickness on the whole surface of the support is ensured. To further assist uniform formation of the coating of the lipid solution on the packing air or an inert gas such as nitrogen may be introduced in counter-current fashion for a period of time. The gas is usually cold however, under certain conditions it may be desirable that the temperature of the gas is chosen such that drying and expansion of the lipid film is assisted or performed using a hot gas.

After drying and expansion of the deposit consisting of pure or lipids with usual degree of purity into the three dimensional structure, the deposit is contacted with an aqueous carrier phase. Depending on the configuration of the reactor the carrier phase may be introduced at the lower end of the reactor e.g. in the case of trickle tower or fluidized bed configuration or at the top of the reactor column (in case of the fixed array of tubing). The aqueous carrier phase used may be pure or it may contain biologically active substances, contrast agents or both. Virtually any biologically active substance can be entrapped in the liposomes produced according to the invention. Such substances include but are not limited to antibacterial compounds such as gentamycin, antiviral compounds such as rifamycins, antifungal compounds such as amphotericin B, antiparasitic compounds such as derivatives of antimony, antineoplastic compounds such as mitomycin C, doxorubicin and cisplatinum, proteins such as albumin and lipo-proteins, immunoglobulines, toxins such as diphteria toxin, enzymes such as catalase, hormones, neurotransmitters, radio-opaque compounds such as ^{99}Tc, fluorescent compounds such as carboxy fluoroscein, anti-inflammatories such as salicylic acid and ibuprofen, anesthetics such as dibucaine or lidocaine, etc.

Very good results and high entrapment loadings are achieved with iodinated X-ray contrast agents such as iopamidol, iomeprol, iohexol, iopentol, iotrolan, iodixanol, ioglucol, etc. The iodine to lipid ratio of the liposome vesicles according to the invention is at least 2.75.

The evaporation of the organic solvent or the mixure of solvents is carried out at above ambient temperatures or reduced pressure or both. Experiments have shown that the rate of evaporation has a strong influence on the degree of expansion of the lipid structure. Hence for optimal expansion, one will appropriately control the amount of heat and the pressure within the reactor. The control becomes particularly important near the end of solvent evaporation, i.e. when the solution thickens and becomes viscous. At this point, a slight reduction of pressure will result in a relatively fast expansion (foaming). It has been established that by balancing the temperature and pressure for a given solvent or solvent mixture different degrees of expansion of the lipid deposit may be achieved. Best results are obtained when the organic solvent is selected from petroleum ether, chloroform, methanol, ethanol, propanol, iso-propanol, n-butanol, tert-butanol, pentanol, hexanol, pentane, hexane, heptane, cyclohexane and mixtures thereof. Preferably the solvent is an azeotropic mixture of two solvents. Good results have been obtained with azeotropic mixtures of ethanol with cyclohexane, chloroform with methanol and iso-propanol with hexane.

Lipids used for production of liposome vesicles are conventional and are selected from synthetic or natural, saturated and/or unsaturated phospholipids including phosphatidylcholine, phosphatidylethanol-amine, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol and phosphatidic acid. The following phospholipids are particularly useful dipalmitoylphosphatidyl choline, dipalmitoylphosphatidyl glycerol, dipalmitoylphosphatidyl acid, dipalmitoylphosphatidyl ethanol-amine and the corresponding distearoyl- and dimyristyl- counterparts and mixtures thereof. Those lipids or their mixtures may further contain substances selected from dicetylphosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, α-tocopherol, stearic acid, stearyl amine and mixtures thereof.

The invention also includes a supported or unsupported three dimensional structure of expanded dry lipids with density of below .1g/cm^3, preferably below .08 g/cm^3 and more preferably with the density of between .05 and .01 g/cm^3. By supported structure it is meant that the lipid porous deposit is formed on an array of inert supporting material.

The expanded three dimensional lipid structures are extremely useful for the manufacture of liposomes with high entrapment capacity particularly when these liposomes are used to carry drugs or diagnostic contrast agents. In such a case the porous three dimenssional lipid structure is contacted with an aqueous solution containing the drug or the diagnostic agent as an active ingredient whereby liposomes will form and encapsulate the ingredient. The liposomes carrying the active substance are then processed as appropriate in a conventional way. Alternatively, a suspension of "empty" liposome vesicles i.e. liposome vesicles containing only aqueous liquid carrier may be formed first. In the subsequent step these "empty" liposomes are contacted with a solution containg an active ingredient and the vesicles loaded using for example trans-membrane loading technique.

The invention further comprises an apparatus for the manufacture of liposomes with high entrapment capacity comprising a reaction vessel with an inlet and an outlet, a connection to a vacuum, means for cooling or heating, a control means, and a packing, characterised in that the packing is an array of a closely packed tubing of an inert material. The tubing having the inner diameter of between .5 mm and 5 mm and the wall thickness of between .5 and 2 mm is preferably arranged in a vertical fashion although a coil-like arrangement is also possible.

The following examples further illustrate the invention:

Example 1

Reactor Characterisation

A vertical, thermoregulated, 1 meter high, 316L stainless steel column with inner diameter of 50 mm fitted at its bottom end with a metal grid was filled with 12 stainless steel tubes. The inner diameter of the tubing was 4 mm and wall thickness of 1 mm. Prior to insertion into the reactor the tubing was spot welded to form an array of parallel tubes. The same reactor configuration but with tubing of 2 mm and 3 mm diameter have also been prepared and tested.

Prior to the tests directed to expansion of the lipid deposits

characterisation of the reactor was carried out by deposition of non-expanded lipid films using the following lipid composition: hydrogenated soy lecithin/dicetylphosphate in 9:1 molar ratio. Experiments were performed to determine the best conditions for the deposition of the lipids in the tubes and to establish the impact of the lipid concentration, internal diameter and nature of the tubes and rate of drainage of the lipid solution. In all cases, the lipid solutions in chloroform were introduced into the tubes at room temperature and after filling of the tubes from the bottom the lipid solutions were drained at a controlled rate. The deposit was dried at 80°C under nitrogen by evaporation of the solvent and the dry deposit rinsed 3 times with a small amount of chloroform.

TABLE 1

Lipid conc. g/l	Lipids deposited in mg of lipid/100 cm^2	
	3 mm tube	4 mm tube
180	33.1	23.3
220	43.7	29.7
260	62.5	40.0
300	81.5	56.5
320	94.5	80.4
340	111.3	84.2

As shown in Table 1 and Figure 3 the amounts of lipids deposited at various lipid concentrations and two different diameters of stainless steel tubing the lipid coating increases with an increase of the lipid concentration. In addition, thicker deposits per unit area are obtained in the 3 mm tubing than in 4 mm. In both cases the amounts of lipids deposited appear to be proportional to the square of the lipid concentration.

As it can be seen from Table 2, the amount of lipids deposited increases with the rate of drainage. However, if these results are expressed as a function of the drainage velocity (in cm per min) rather than drainage flow rate (in ml per min) amounts of the lipids deposited appear to be nearly proportional to the linear velocity. That independently of the actual tube size. See Figure 4.

TABLE 2

Drainage rate ml/min	Lipids deposited in mg lipid/100 cm^2 in a tube of 2 mm	3 mm	4 mm
1	55.2	55.3	37.4
2	76.5	63.0	47.3
3.75	114.9	83.7	65.4
5	121.0	94.5	80.4

Additional experiments were carried out in the identical set up but using glass tubes instead of stainless steel ones have shown that there are no major differences between the two supports with regard the lipid deposition. The homogeneity of the lipid coating was determined by cutting the coated steel tubes from the top in 10 cm intervals and measuring the film thickness. The results obtained are given in Table 3.

TABLE 3

Fraction	Lipids deposited in mg 3 mm tube	4 mm tube
1	5.15	5.13
2	6.63	3.77
3	7.22	4.52
4	8.20	3.50
5	7.59	5.58
6	6.55	6.16
7	5.59	6.38
8	5.63	6.21
9	5.22	6.97
10	9.06	6.86
Mean ± S.D.	**6.68 ± 1.33**	**5.51 ± 1.24**

Calculation of apparent (bulk) densities of the lipid deposits obtained in the three different reactor configurations have shown that for 2mm tubing bulk densities were between .04 and .06 g/cm^3, for 3mm

tubing between .02 and .04 g/cm^3 and for 4mm tubing the bulk densities were between .01 and .03 g/cm^3.

Liposome production

After the characterisation, a new reactor with 250 stainless steel tubes was made and connected into the circuit shown in Figure 5. 26 g of hydrogenated soy phosphatidylcholine (Nattermann) with 2 g of dicetylphosphate and 106 g of chloroform were placed into 1 liter glass reactor equiped with stirrer, heating jacket, and condenser (1) and heated to 60 °C under stirring until complete dissolution. The lipid solution filtered through the sterile filter (3) and loaded into 316 L stainless steel column with a heating jacket filled with 250 of parallel 1 m long 304 stainless steel tubes (4) by means of the peristaltic pump (2). The excess of solution was removed, the solvent evaporated and the lipids deposited at 80°C by circulating air from the bottom of the column.

The 2 liter glass reactor with stirrer, heating jacket, condenser (5) was filled with 849 g of iopamidol, 1196 g of water, .54 g of EDTA and 1.60 g of Tris and heated at 90°C under stirring until complete solubilization was obtained. The iopamidol solution was then filtered, transferred to the glass reactor (6) and therefrom to the column (4). The solution was circulated at 75°C between the reactor (6) and the column (4) by means of the gear pump (7). The liposome suspension formed was then extruded through the filter (8), recovered in the reactor (9) and then concentrated using the microfiltration system (10) by means of pump (11). The concentrated solution was washed with saline (12) to eliminate free iopamidol (diafiltration). Typical iodine to lipid ratios (I/L) for a number of experiments run under different experimental condition were in the range 2.5-3.5 with lipid concentrations between 25 and 35 mg/ml with the liposome mean size of 570 nm.

The production unit can be sterilised (e.g. steam) and is envisaged as a closed-circuit aseptic large scale production unit.

Example 2

The Example 1 was repeated in the experimental set-up shown in

Figure 5 but size was scaled-up by a factor four. 518.6 g of hydrogenated soy phosphotidylcholine (Nattermann) with 41.4 g of dicetylphosphate and chloroform 2130.0 g were placed into 3 liter glass reactor equiped with stirrer, heating jacket, and condenser (1) and heated to 60 °C under stirring until complete dissolution. The lipid solution was filtered on the 0.22 µm sterile filter (3) using the peristaltic pump (2). The lipid solution is then transfered into the 316 L stainless steel column with a heating jacket filled with 1000 of parallel 1 m long 304 stainless steel tubes (4) and the excess of the lipid solution removed. The chloroform was evaporated and the lipids dry deposited at 80°C by circulating air from the bottom of the column.

The 7 liter stainless steel (316L) reactor with stirrer, heating jacket, condenser (5) was loaded with 2920 g of iopamidol, 4110 g of water, 1.87 g of EDTA and 5.50 g of Tris (HCl qsp for pH 7.2) and heated at 90°C under stirring until complete solubilization was obtained. The iopamidol solution was then passed through the sterile filter (not shown), transferred to column (4) using the gear pump (7) and circulated at 75°C between the reactor (6) and the column (4) for a while. The liposome suspension formed was recovered in the reactor (6), extruded through the filter (8) at 75 °C and the liposomes recovered in reactor (9). The liposome solution was then concentrated using the microfiltration system (10). Typical iodine to lipid ratios (I/L) for a number of experiments run under different experimental condition were in the range 2.5-3.5 with lipid concentrations between 25 and 35 mg/ml with the liposome mean size of 570 nm. Bulk density of the lipid deposit varied as a function of the experimental conditions and was estimated to be between .08 and .05 g/cm^3. However the best liposomes were prepared with the bulk densities between .01 and .02 g/cm^3.

Example 3

The Example 2 was repeated using as solvent the azeotropic mixture of chloroform and methanol (87/13 = v/v). After evaporation of the solvent under reduced pressure 60°C warm distilled water was added to the reactor. The temperature of the water added was above the transition temperature (54°C) of the lipids used. The expanded three dimensional lipids deposit obtained was allowed to hydrate and the liposomes formed were distributed homogeneously through the liquid.

Liposomes of the MLV type were formed in high yield. After about 1 hour, the liposome suspension containing 5 mg/ml of lipids was extruded at 60°C through a 2 μm polycarbonate membrane (Nuclepore) and, after cooling to room temperature, it was concentrated to 30 mg/ml by microfiltration using a 0.22 μm microfilter system Prostak (Millipore).

To the concentrated liposome suspension, there was added 1 liter of an aqueous solution containing 1040 g of (S)-N,N'-bis [2-hydroxy-1-(hydroxymethyl)-ethyl]-2,4,6-triiodo-5-lactamido-isophtalamide (iopamidol) i.e. 520 g/l of covalent iodine at 60°C. The resulting mixture (2 l) with iodine concentration of 260 g/l was incubated for about 30 min at 60°C, after which time the iodine concentration outside and inside the liposome core had equalized. The resulting preparation was concentrated to 30 g lipids/l. The entrapped iodine to lipid ratio (I/L) was about 4.0.

Example 4

A glass column (500 mm high and 50 mm in diameter) was filled with Raschig rings and operated as a trickle tower reactor. A lipid solution containing 50 g/l of a mixture of distearoylphosphatidyl choline (DSPC), cholesterol and dicetylphosphate with molar ratio 5:4:1 in chloroform was trickled down the column fitted with 35 layers of Raschig rings spread over a nickel mesh as a support until the last layer at the bottom was thouroughly soaked with the solution. The excess of the solution was removed and a stream of hot (80°C) nitrogen blown from the bottom up through the reactor. The lipid deposit was dried for 2 hours. The nitrogen flow stopped and the reactor connected to a vaccum (1-2 Torr) and the deposit allowed to dry untill all chloroform was removed. After evaporation of the solvent iomeprol solution with iodine concentration of 260 g/l was added at 60°C to the reactor. The expanded three dimensional lipid deposit was allowed to hydrate for 30 minutes. The liposomes suspension was extuded at 60°C through a 2 μm polycarbonate membrane (Nuclepore) and after cooling to room temperature it was concentrated to 30 g lipids/l. The entrapped iodine to lipid ratio (I/L) was above 4.0.

The same experiment was then repeated with reticulated carbon, reticulated nickel and reticulated glassy carbon as the column packing.

Bulk densities of the three dimensional lipid stucture obtained in these experiments were between .05 and .005 g/cm^3. Liposomes with lipid to iodine ratio of 3.5-4.5 were obtained.

Example 5

A glass column (500 mm high and 50 mm in diameter) filled with hollow glass beads as an array of inert packing and operated as a fluidized bed reactor. A lipid solution containing 50 g/l of a mixture of dipalmitoylphosphatidylcholine (DPPC), cholesterol and dipalmitoyl-phosphatidic acid (DPPA) with molar ratio 5:4:1 in cyclohexane/ethanol azeotropic mixture (69.5/30.5 v/v) was introduced into the column containing a 100 mm high bed of hollow glass spheres supported by a porous glass frit. The solution was allowed to thoroughly wet the glass beads and the excess removed. A stream of hot (80°C) air was blown from the bottom through the reactor and the spheres were fluidized untill the lipid deposit was almost dry. The air flow was then stopped, the reactor connected to a vaccum (1-2 Torr) and the deposit allowed to dry untill complete removal of solvents. After evaporation of the solvent, a 4% by weight lidocaine HCl solution in water (pH 7.2) at 60°C was added to the reactor. The liposome solution formed was extruded at 80°C through a 2 µm polycarbonate membrane (Nuclepore) and after cooling to room temperature concentrated to 35 mg lipid/ml. The entrapped lidocaine in liposomes was .35 mmol lidocaine/g lipid.

Various expansions (20-80%) of the bed during the fluidization showed little influence on the quality of the deposit.

Example 6

The Example 4 was repeated using a 500 mm high glass column without inert packing. The column was filled with 100 ml of lipid solution (80 g/l) prepared from azeotropic mixtures of ethanol/cyclohexane, chloroform/methanol and iso-propanol/hexane. The organic solvent was first evaporated at 55°C and 300 mmHg of pressure and then 70°C and 10 mmHg until formation of a foamed dry deposit. In all cases the three dimensional expanded lipid stucture obtained was then hydrated at 70°C with an aqueous solution of iomeprol to produce liposome encapsulated

iomeprol suspensions. After extrusion at 70°C on a .6 μm polycarbonate membrane (Nuclepore) the liposome suspension was concentrated. Typical iodine to lipid ratios (I/L) for a number of experiments run under different experimental conditions were in the range 1.9-2.5 with lipid concentrations between 25 and 35 mg/ml. Bulk densities of the expanded lipid structure were estimated to be between .05 and .001 g/cm^3.

Claims

1. A liposome vesicle precursor in the form of a dry lipid deposit, characterised in that the lipid deposit is a three dimensional expanded structure with bulk density of below .1 g/cm^3, and preferably below .08 g/cm^3.

2. The vesicle precursor of claim 1, wherein the bulk density of the expanded three dimensional lipid deposit is between .05 and .001.

3. The vesicle precursor of claim 2, wherein the bulk density of the expanded three dimensional lipid deposit is between .02 and .01.

4. The vesicle precursor of claim 1, wherein the expanded three dimensional structure is supported by a network of inert porous material.

5. The vesicle precursor of claim 4, wherein the inert porous material comprises an array of tubing or an array of inert packing.

6. The vesicle precursor of claim 5, wherein the tubing has an inner diameter between .5mm and 5mm and wall thickness between .5 and 2mm.

7. The vesicle precursor of claim 5, wherein the inert packing is selected from hollow glass spheres, reticulated carbon, reticulated vitreous carbon, reticulated metal, glass or metal wool and glass or metal fibre.

8. The vesicle precursor of any of preceeding claims, wherein the lipids are selected from synthetic or natural, saturated and unsaturated phospholipids including phosphatidic acid, phosphatidyl choline, phosphatidylethanol amine, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol and mixtures thereof.

9. The vesicle precursor of claim 8, wherein the lipids further contain substances selected from dicetylphosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, α-tocopherol, stearic acid, stearyl amine and mixtures thereof.

10. A method of making liposome vesicles with enhanced entrapment capacity by dissolving one or more film forming lipids in at least one organic solvent to form a solution in a reaction vessel, depositing the lipids by evaporation of the solvent, contacting the lipid deposit with an aqueous solution carrier phase, and producing liposome vesicles entrapping the carrier solution, characterised in that the lipid deposit obtained by evaporation of the solvent is an expanded three dimensional structure whose bulk density is below .1 g/cm^3 and preferably below .08 g/cm^3.

11. The method of claim 10, wherein the bulk density is between .05 and .001 g/cm^3.

12. The method of claim 10, wherein the reaction vessel contains a network of inert porous material or packing which serves as a support or matrix for the deposition of lipids.

13. The method of claim 12, wherein the packing is selected from reticulated carbon, reticulated vitreous carbon, reticulated metal, glass or metal wool and glass or metal fibre.

14. The method of claim 12, wherein the inert porous packing are hollow glass spheres which are fluidized.

15. The method of claim 12, wherein the inert packing comprises Raschig rings packed in a column as the reaction vessel and the lipid solution is introduced from the top in a trickle fashion.

16. The method of claim 10, wherein after evaporation of the organic solvent the lipid deposit is contacted with the aqueous carrier phase and which is introduced at the lower end of the column.

17. The method of claim 10, wherein the evaporation is carried out at above ambient temperature or reduced pressure.

18. The method of claim 10 or 12, wherein the evaporation is carried out by means of blowing air or an inert gas, preferrably nitrogen, through the reaction vessel.

19. The method of claim 10 or 12, wherein the organic solvent is selected from chloroform, petroleum ether, methanol, ethanol, propanol, iso-propanol, n-butanol, tert-butanol, pentanol, hexanol, pentane, hexane, heptane, cyclohexane and mixtures thereof.

20. The method of claim 19, wherein the organic solvent is an azeotropic mixture of two solvents.

21. The method of claim 20, wherein the solvent is a mixture of ethanol and cyclohexane, chloroform and methanol, or isopropanol and hexane.

22. The method of claim 10, wherein the aqueous carrier phase contains a biologically active substance.

23. The method of claim 22, wherein the active substance is a contrast agent.

24. The method of claim 23, wherein the contrast agent is an iodinated X-ray contrast agent.

25. The method of claim 24, wherein the iodine to lipid ratio of the liposome vesicles is at least 2.75.

26. A liposome vesicle suspension comprising a dispersion of hydrated lipid particles in a carrier liquid, characterised in that the vesicles are obtained by the hydration and dispersion of the liposome vesicle precursor of claim 1-9 in said carrier.

27. A contrast agent comprising a suspension of liposome vesicles of claim 26.

28. Use of the three dimensional lipid structures of claims 1-9 for the manufacture of liposomes with high entrapment capacity.

29. Use of the three dimensional lipid structures of claims 1-9 for the manufacture of diagnostic contrast agents.

30. An apparatus for the manufacture of liposomes with high entrapment capacity according to the method of claims 10-25, comprising a reaction vessel with an inlet and an outlet, a connection to a vacuum, means for cooling or heating, a control means, and a packing, characterized in that the packing is an array of a closely packed tubes of an inert material, the tubes having an inner diameter of between .5mm and 5mm and the wall thickness of between .5 and 2mm.




FIGURE 1




FIGURE 2:




FIGURE 3




FIGURE 4



12
0.2µ
5
air
exhaust
saline
10
parallel
tube
column
iopamidol
micro
filtration
module
iopamidol
or waste
4
water 75°C
6
0.2µ
0.2µ
3
0.2µ
water
75°C
vent
11
chloroform
drain
air
7
0.2µ
8
2
3x 2µ
hot water
drain
9
1
lipids or
chloroform

FIGURE 5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 95/00802

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 119 020 (E.R. SQUIBB & SONS, INC.) 19 September 1984 see page 4, line 1 - page 5, line 26 see page 8, line 1 - page 9, line 11 see page 11 - page 12; examples 1,2 see page 13; example 4 see claims 1-6,13-15,17-24,26,28-32 ---	1-4, 8-12, 17-19, 22-24, 26-29
X	EP,A,0 186 352 (TECHNICON INSTRUMENTS CORPORATION) 2 July 1986 see the whole document see page 13, line 23 - line 25 --- -/--	1-4, 8-12, 17-19, 22,26,28

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 December 1995	04.01.96

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Benz, K

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inte: nal Application No
PCT/IB 95/00802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE,A,33 35 701 (LIPODERM PHARMACEUTICALS LTD.) 5 April 1984 see the whole document see page 17 - page 18; example 3	1-4, 8-12, 17-19, 22,26,28
X	EP,A,0 087 993 (PARFUMS CHRISTIAN DIOR) 7 September 1983 see page 24; example 10	1-4, 8-12, 17-19, 22,26,27
A	J. FALBE U. M. REGITZ 'RÖMPP-CHEMIE-LEXIKON, 9TH EDITION, VOL.3' 1990 , GEORG THIEME VERLAG , STUTTGART (DE) *PAGES 1860-1861, "HPLC"*	5-8, 13-16,30

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter ...nal Application No
PCT/IB 95/00802

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0119020	19-09-84	GB-A-	2134869	22-08-84
		GB-A-	2135268	30-08-84
		GB-A-	2135647	05-09-84
		AU-B-	576313	25-08-88
		AU-B-	2427484	23-08-84
		CA-A-	1236019	03-05-88
		DE-A-	3471585	07-07-88
		EG-A-	17037	30-12-93
		JP-C-	1840072	25-04-94
		JP-A-	59173133	01-10-84
EP-A-0186352	02-07-86	US-A-	4619795	28-10-86
		AU-B-	574985	14-07-88
		AU-B-	5078685	03-07-86
		CA-A-	1260394	26-09-89
		DE-A-	3586095	25-06-92
		JP-A-	61180713	13-08-86
DE-A-3335701	05-04-84	US-A-	4485054	27-11-84
		CA-A-	1205383	03-06-86
		JP-A-	59134712	02-08-84
EP-A-0087993	07-09-83	FR-A-	2521565	19-08-83
		CA-A-	1208133	22-07-86
		JP-B-	1050449	30-10-89
		JP-C-	1570147	10-07-90
		JP-A-	59031707	20-02-84
		US-A-	4508703	02-04-85